Comparison of the value of different biomarkers as diagnostic and prognostic markers in AECOPD
Signa Vitae, cilt.21, sa.5, ss.86-95, 2025 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 21 Sayı: 5
- Basım Tarihi: 2025
- Doi Numarası: 10.22514/sv.2025.070
- Dergi Adı: Signa Vitae
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Central & Eastern European Academic Source (CEEAS), EMBASE
- Sayfa Sayıları: ss.86-95
- Anahtar Kelimeler: Chronic obstructive pulmonary disease, Exacerbations, Pro-BNP, Procalcitonin
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Background: Acute exacerbations of chronic obstructive pulmonary disease (AE-COPD) are a significant cause of admissions to emergency departments (ED) and play a key role in morbidity and mortality rates on a global scale. Patients with AECOPD are frequently treated by emergency medicine (EM) physicians who must accurately predict the severity and potential outcomes of these cases. Treatment decisions and the extent of intervention provided often hinge on these predictions. In our study, we aimed to evaluate and compare the efficacy of different biomarkers—Procalcitonin (PCT), Pro-Brain Natriuretic Peptide (Pro-BNP) and C-Reactive Protein (CRP)—in determining the severity and prognosis of AECOPD. Methods: We examined the data of 196 selected patients diagnosed with AECOPD who were admitted to our ED between 15 February 2023 and 15 February 2024. The Receiver Operating Characteristic (ROC) curve was used to demonstrate the sensitivity and specificity of the relevant biomarkers. Results: Pro-BNP was found to be a significant predictor for severe AECOPD at ≥1350 ng/L and for mortality at ≥1500 ng/L (the area under curve (AUC): 0.653, 0.758). PCT showed lower predictive performance for mortality compared to Pro-BNP (AUC: 0.627). Although CRP levels were elevated in both severity and mortality groups, it did not demonstrate significant differences in predicting disease severity or mortality. Conclusions: Pro-BNP and PCT hold promise as crucial biomarkers for the management of AECOPD. They could enable prompt initiation of advanced treatment and enhance the overall care for individuals with AECOPD. Clinical Trial Registration: The study was registered on ClinicalTrials.gov (NCT06514599).